+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Exocrine Pancreatic Insufficiency - Global Market Trajectory & Analytics

  • ID: 5309900
  • Report
  • April 2021
  • Region: Global
  • 130 pages
  • Global Industry Analysts, Inc
Global Exocrine Pancreatic Insufficiency Market to Reach $5.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Exocrine Pancreatic Insufficiency estimated at US$3.9 Billion in the year 2020, is projected to reach a revised size of US$5.8 Billion by 2027, growing at a CAGR of 5.8% over the period 2020-2027. Therapeutics, one of the segments analyzed in the report, is projected to record 5.5% CAGR and reach US$3.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Diagnostics segment is readjusted to a revised 6.2% CAGR for the next 7-year period.



The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 5.4% CAGR

The Exocrine Pancreatic Insufficiency market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1 Billion by the year 2027 trailing a CAGR of 5.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.4% and 4.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Select Competitors (Total 46 Featured):
  • AbbVie, Inc.
  • Allergan PLC
  • Anthera Pharmaceuticals, Inc.
  • AzurRx BioPharma, Inc.
  • Cilian AG
  • Digestive Care, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Nordmark Arzneimittel GmbH & Co. KG
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Exocrine Pancreatic Insufficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Exocrine Pancreatic Insufficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Exocrine Pancreatic Insufficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 10: USA Current & Future Analysis for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 11: USA Historic Review for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 12: USA 15-Year Perspective for Exocrine Pancreatic Insufficiency by Type - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2020 & 2027
  • CANADA
  • Table 13: Canada Current & Future Analysis for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 14: Canada Historic Review for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 15: Canada 15-Year Perspective for Exocrine Pancreatic Insufficiency by Type - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2020 & 2027
  • JAPAN
  • Table 16: Japan Current & Future Analysis for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 17: Japan Historic Review for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 18: Japan 15-Year Perspective for Exocrine Pancreatic Insufficiency by Type - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2020 & 2027
  • CHINA
  • Table 19: China Current & Future Analysis for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 20: China Historic Review for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 21: China 15-Year Perspective for Exocrine Pancreatic Insufficiency by Type - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2020 & 2027
  • EUROPE
  • Table 22: Europe Current & Future Analysis for Exocrine Pancreatic Insufficiency by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 23: Europe Historic Review for Exocrine Pancreatic Insufficiency by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 24: Europe 15-Year Perspective for Exocrine Pancreatic Insufficiency by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 25: Europe Current & Future Analysis for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: Europe Historic Review for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 27: Europe 15-Year Perspective for Exocrine Pancreatic Insufficiency by Type - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2020 & 2027
  • FRANCE
  • Table 28: France Current & Future Analysis for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 29: France Historic Review for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 30: France 15-Year Perspective for Exocrine Pancreatic Insufficiency by Type - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2020 & 2027
  • GERMANY
  • Table 31: Germany Current & Future Analysis for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: Germany Historic Review for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 33: Germany 15-Year Perspective for Exocrine Pancreatic Insufficiency by Type - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2020 & 2027
  • ITALY
  • Table 34: Italy Current & Future Analysis for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 35: Italy Historic Review for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 36: Italy 15-Year Perspective for Exocrine Pancreatic Insufficiency by Type - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
  • Table 37: UK Current & Future Analysis for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: UK Historic Review for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 39: UK 15-Year Perspective for Exocrine Pancreatic Insufficiency by Type - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2020 & 2027
  • REST OF EUROPE
  • Table 40: Rest of Europe Current & Future Analysis for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 41: Rest of Europe Historic Review for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 42: Rest of Europe 15-Year Perspective for Exocrine Pancreatic Insufficiency by Type - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
  • Table 43: Asia-Pacific Current & Future Analysis for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: Asia-Pacific Historic Review for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 45: Asia-Pacific 15-Year Perspective for Exocrine Pancreatic Insufficiency by Type - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2020 & 2027
  • REST OF WORLD
  • Table 46: Rest of World Current & Future Analysis for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 47: Rest of World Historic Review for Exocrine Pancreatic Insufficiency by Type - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 48: Rest of World 15-Year Perspective for Exocrine Pancreatic Insufficiency by Type - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 46
Note: Product cover images may vary from those shown
Adroll
adroll